{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:27:35Z","timestamp":1786998455266,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ymthe.2023.08.012","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T01:18:32Z","timestamp":1692753512000},"page":"2554-2556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advancing in\u00a0vivo genome editing: B cell engineering via adenoviral delivery systems"],"prefix":"10.1016","volume":"31","author":[{"given":"Amaia","family":"Cadinanos-Garai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2903-9040","authenticated-orcid":false,"given":"Mohamed","family":"Abou-el-Enein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.08.012_bib1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy","volume":"2","author":"Abou-el-Enein","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ymthe.2023.08.012_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T\u00a0cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.012_bib3","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809158","article-title":"In\u00a0vivo generation of human CD 19- CAR T\u00a0cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2023.08.012_bib4","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In\u00a0Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.012_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific t\u00a0cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2023.08.012_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T\u00a0cells produced in\u00a0vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2023.08.012_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2023.08.012_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2023.07.004","article-title":"Adenoviral vectors infect B lymphocytes","author":"Rice-Boucher","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.012_bib9","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1016\/j.ymthe.2021.09.019","article-title":"Genome edited B cells: a new frontier in immune cell therapies","volume":"29","author":"Rogers","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.012_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30358-0","article-title":"Engineering of Primary Human B cells with CRISPR\/Cas9 Targeted Nuclease","volume":"8","author":"Johnson","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2023.08.012_bib11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2017.11.012","article-title":"Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells","volume":"26","author":"Hung","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.012_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.isci.2019.01.032","article-title":"CRISPR-Mediated Editing of the B Cell Receptor in Primary Human B Cells","volume":"12","author":"Greiner","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2023.08.012_bib13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41419-020-03187-1","article-title":"Engineering of \u03b1-PD-1 antibody-expressing long-lived plasma cells by CRISPR\/Cas9-mediated targeted gene integration","volume":"11","author":"Luo","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2023.08.012_bib14","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41587-022-01328-9","article-title":"In\u00a0vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat. Biotechnol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623004446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623004446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:10:06Z","timestamp":1761502206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001623004446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1525001623004446"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.08.012","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing in\u00a0vivo genome editing: B cell engineering via adenoviral delivery systems","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}